Ziopharm Oncology to Participate in Jefferies Virtual London Healthcare Conference on November 19, 2020

Rhea-AI Summary

BOSTON, Nov. 13, 2020 – Ziopharm Oncology (Nasdaq: ZIOP) announced that Laurence Cooper, M.D., Ph.D., CEO, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 1:45 pm ET. Investors can access the live webcast and archived recording on the company’s website.

Ziopharm is focused on developing non-viral and cytokine-driven cell therapies to treat solid tumors, utilizing the Sleeping Beauty gene transfer platform for scalable therapies, with partnerships in clinical research.

BOSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020 at 1:45 pm ET.

To access the live webcast presentation, or the subsequent archived recording, please visit the “Investors” section of the Ziopharm website at www.ziopharm.com.

About Ziopharm Oncology, Inc.
Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit www.ziopharm.com

Investor Relations Contacts:
Ziopharm Oncology:
Chris Taylor
VP, Investor Relations and Corporate Communications
T: 617.502.1881
E: ctaylor@ziopharm.com

LifeSci Advisors:
Mike Moyer
Managing Director
T: 617.308.4306
E: mmoyer@lifesciadvisors.com

Media Relations Contact:
LifeSci Communications:
Patrick Bursey
T: 646.876.4932
E: pbursey@lifescicomms.com

FAQ

What event will Laurence Cooper from ZIOP participate in?

Laurence Cooper will participate in the Jefferies Virtual London Healthcare Conference on November 19, 2020.

What is the date and time of ZIOP's presentation at the conference?

The presentation will take place on November 19, 2020, at 1:45 pm ET.

How can I access the ZIOP conference webcast?

The live webcast and archived recording can be accessed in the Investors section of Ziopharm's website.

What is Ziopharm's focus in oncology?

Ziopharm focuses on developing non-viral and cytokine-driven therapies to treat solid tumors.

What technology does ZIOP use for its therapies?

Ziopharm employs the Sleeping Beauty gene transfer platform for its T-cell receptor therapies.